

Nanopharmaceuticals Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma

Initiation of Clinical Study Testing the Addition of an Anti-Cancer Drug, Triapine®, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

ALACHUA, FL, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- Nanopharmaceuticals, Inc., a clinical-stage pharmaceutical development company, announced initiation a Phase 1 clinical study sponsored by the National Cancer Institute, part of the National Institutes of Health, titled "Testing the Addition of an Anti-Cancer Drug, [Triapine®](#), to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma" (NCI protocol 10669, ClinicalTrials.gov Identifier: NCT06860594). The primary objective of the phase 1 study will be to identify the safety and maximally tolerated dose (MTD) of oral Triapine® used in combination with radiation therapy for patients with recurrent glioblastoma (GBM) or astrocytoma. The Principal Investigator is Stephanie M Yoon, City of Hope Comprehensive Cancer Center Lead Academic Organization, and the study will recruit 30 patients. The study will be performed under a Cooperative Research and Development Agreement (CRADA) between NCI and Nanopharmaceuticals and conducted by the NCI funded Experimental Therapeutics Clinical Trials Network (ETCTN).

This phase I trial tests the safety, side effects, and best dose of Triapine® in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine® may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving Triapine® in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

About Triapine®

Triapine® is a synthetic heterocyclic carboxaldehyde thiosemicarbazone with potential antineoplastic activity being studied in the treatment of cancer. It is a type of ribonucleotide reductase inhibitor. Also called 3-aminopyridine-2-carboxaldehyde thiosemicarbazone and 3-AP, Triapine® inhibits the enzyme ribonucleotide reductase, resulting in the inhibition of the conversion of ribonucleoside diphosphates to deoxyribonucleotides necessary for DNA synthesis.

About Nanopharmaceutics, Inc.

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver Biopharmaceutics Classification System (BCS) category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability. Nanopharmaceutics is a subsidiary of TRON Group Inc. (OTC:TGRP).

James D Talton
Nanopharmaceutics, Inc.
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/799120203>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.